Acquisition of assets from Universal Pharmacy Ltd

1 October 2025

MedPal AI plc

("MedPal AI" or the "Company")

MedPal AI plc Acquires Assets from Universal Pharmacy Limited

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence ("AI") company focused on wellness management, announces the acquisition, through its wholly owned subsidiary, MedPal Limited, of key assets from Universal Pharmacy Limited ("Universal") (in administration) for £45,000 in cash (the "Acquisition"). The assets acquired include a leasehold property, goodwill, certain equipment and stock and Universal's NHS Pharmacy Contract which is a UK Distance Selling Pharmacy (DSP) licence. The Directors consider this licence to be strategically important as it will enable MedPal AI (via its subsidiary Medpal Limited) to provide regulated online and mail-order pharmaceutical services. Completion of the Acquisition is conditional, inter alia, upon Medpal Limited's successful application to NHS England for approval on its fitness to practice and change of ownership in respect of the NHS Pharmacy Contract previously held by Universal. The consideration is payable as to £15,000 on signing the agreement and £30,000 on completion, once the licence application has been approved.

In conjunction with the Acquisition, MedPal AI announces the appointment of Mike Rudin as Director of Online Pharmacy. Mike was formerly employed by Tesco Limited as Director of Pharmacy and Superintendent Pharmacist where he led the establishment of the UK's largest in-store pharmacy chain, spanning 200 outlets with annual turnover over £200 million. His expertise will drive MedPal AI's online pharmacy operations. More recently he has held senior management positions or directorships in business services, financial, pharmaceutical and wholesale companies.

MedPal AI's AI-powered app aggregates health data for personalised recommendations, including support for weight management. The Acquisition strategically positions MedPal AI in the rapidly growing GLP-1 agonist market for obesity treatment, including drugs such as semaglutide (eg. Ozempic and Mounjaro). As of September 2025, approximately 2.2 million UK adults (4.1% of the adult population)1 use GLP-1 drugs, with an average monthly cost of £200 per patient2, representing a target market opportunity exceeding £440 million in monthly revenue.

The Acquisition and appointment of Mike Rudin underscore MedPal AI's commitment to innovative, AI-enhanced healthcare.

Jason Drummond, Chief Executive Officer of MedPal AI, said:

"We are delighted to have been able to make this opportunistic yet strategically important acquisition. We will be making an investment into the business both to support its modernisation with the latest technology and to enable it to grow revenues rapidly. We also warmly welcome Mike Rudin as our new Director of Online Pharmacy. As one of the experienced senior superintendent pharmacists in the UK, Mike will be a major asset to MedPal AI and his expertise will be instrumental in driving our online pharmacy operations and revenues."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company take responsibility for the contents of this announcement.

Enquiries:

MedPal AI plc via Square1 Consulting

Jason Drummond, Chief Executive Officer

Cairn Financial Advisers LLP +44 20 7213 0880

Louise O'Driscoll/Jo Turner

Clear Capital Markets Limited +44 20 3869 6080

Bob Roberts/ Nick Josh

Square1 Consulting +44 20 7929 5599

David Bick +44 7831 381201

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events. 

1 https://www.kantar.com/uki/inspiration/fmcg/2025-wp-glp-1-agonists-the-next-big-disruptor-in-society

2 Compare the Cost of Weight Loss Injections in 2025 - The Best Of Health